Preferred Name |
Lansoprazole |
|
Synonyms |
Lansoprazole LANSOPRAZOLE Prevacid |
|
Definitions |
A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C29150 |
|
CAS_Registry |
103577-45-3 |
|
CHEBI_ID |
CHEBI:6375 |
|
Chemical_Formula |
C16H14F3N3O2S |
|
code |
C29150 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
|
Contributing_Source |
FDA HemOnc |
|
DEFINITION |
A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties. |
|
FDA_UNII_Code |
0K5C5T2QPG |
|
FULL_SYN |
Lansoprazole LANSOPRAZOLE Prevacid |
|
label |
Lansoprazole |
|
Legacy Concept Name |
Lansoprazole |
|
NCI_Drug_Dictionary_ID |
483101 |
|
PDQ_Closed_Trial_Search_ID |
483101 |
|
PDQ_Open_Trial_Search_ID |
483101 |
|
Preferred_Name |
Lansoprazole |
|
prefixIRI |
Thesaurus:C29150 |
|
Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
UMLS_CUI |
C0050940 |
|
subClassOf |